Tumor-Specific Antigen Market to See 6.2% Annual Growth Through 2023

Growing Prevalence of Cancer and Increasing Investment in Research Driving Expansion

Cancer Cells

The growing prevalence of cancer and increases in funding for research are factors helping to drive the global tumor-specific antigen market, according to a report by BCC Research, “Global Tumor-specific Antigen Market.”

The market expects to see a compound annual growth rate (CAGR) of 6.2% through 2023, when it could be worth $2.4 billion.

Major players in the market include Go Therapeutics, Aivita Biomedical, Creative Diagnostics and Bio-Rad Laboratories.

Research Highlights

  • Non-coding leads the market by size, with a 2018 value of $1.2 billion, while coding had a value of $589.6 million.
  • Growth will be strongest in the Asia-Pacific region, which will have a CAGR through 2023 of 6.7%.
  • North America led the market by size, with a 2018 value of $105.1 million, followed by Europe at $59.0 million and the Asia-Pacific region at $51.1 million.

Read the full report here: https://www.bccresearch.com/market-research/biotechnology/tumor-specific-antigen-market-research-report.html

“Tumor-specific antigen are substances that are produced in tumor cells,” notes report author and BCC Research analyst Sathya Durga. “These substances trigger an immune response in the host. Tumor antigens are not membrane proteins. Instead, they are cytosolic protein derivatives. Tumor antigens are potential candidates for cancer therapy as these are beneficial tumor markers in the identification of tumor cells through diagnostic tests.”

Surge in Cancer Cases Seen as a Major Market Driver

A major market force is the surging numbers of cases of cancer. Cases are particularly high in Central and Western Europe, while major cancer types include breast, colorectal, prostate, tracheal and bronchus. These factors are driving investment in cancer diagnosis and research, with $41.3 million being invested in cancer research for biology in 2016, followed by $17.4 million for cause or etiology and $14.5 million for treatment research.

Editors/reporters requesting analyst interviews should contact Sarah Greenberg at press@bccresearch.com.

Source: BCC Research


Tags: cancer, cancer immunotherapy, cancer research, prevalence of cancer, Tumor-specific antigen


About BCC Research (Demo)

View Website

BCC Research has published high-quality market research since 1971. We provide comprehensive market intelligence about science and technology fields to support academic and corporate needs.

Eric  Surber
Eric Surber
Director of Corporate Marketing, BCC Research (Demo)
BCC Research (Demo)
104 S. Estes Dr. Suite 204
Chapel Hill, NC 27514
United States